BioPorto A/S is an in-vitro diagnostics firm that supplies diagnostic tools and antibodies globally to medical professionals and scientists. Its product portfolio includes the neutrophil gelatinase-associated lipocalin (NGAL) test – a particle-enhanced turbidimetric assay designed to quantify NGAL levels, which complements existing clinical assessments and standard diagnostic procedures. Furthermore, it supplies monoclonal antibodies for scientific, pharmaceutical, and clinical research applications, along with enzyme-linked immunosorbent assay (ELISA) kits, automated in-vitro diagnostic assays, and a versatile rapid assay device platform for developing lateral flow assays. BioPorto distributes its products through its proprietary sales force, an extensive network of distributors, and strategic OEM collaborations. Established in 2000, the company's base of operations is in Hellerup, Denmark.
—
BioPorto A/S is an in-vitro diagnostics firm that supplies diagnostic tools and antibodies globally to medical professionals and scientists. Its product portfolio includes the neutrophil gelatinase-associated lipocalin (NGAL) test – a particle-enhanced turbidimetric assay designed to quantify NGAL levels, which complements existing clinical assessments and standard diagnostic procedures. Furthermore, it supplies monoclonal antibodies for scientific, pharmaceutical, and clinical research applications, along with enzyme-linked immunosorbent assay (ELISA) kits, automated in-vitro diagnostic assays, and a versatile rapid assay device platform for developing lateral flow assays. BioPorto distributes its products through its proprietary sales force, an extensive network of distributors, and strategic OEM collaborations. Established in 2000, the company's base of operations is in Hellerup, Denmark.
—
Daily adjusted close
BioPorto A/S is an in-vitro diagnostics firm that supplies diagnostic tools and antibodies globally to medical professionals and scientists. Its product portfolio includes the neutrophil gelatinase-associated lipocalin (NGAL) test – a particle-enhanced turbidimetric assay designed to quantify NGAL levels, which complements existing clinical assessments and standard diagnostic procedures. Furthermore, it supplies monoclonal antibodies for scientific, pharmaceutical, and clinical research applications, along with enzyme-linked immunosorbent assay (ELISA) kits, automated in-vitro diagnostic assays, and a versatile rapid assay device platform for developing lateral flow assays. BioPorto distributes its products through its proprietary sales force, an extensive network of distributors, and strategic OEM collaborations. Established in 2000, the company's base of operations is in Hellerup, Denmark.